An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing

Jolieke G. van Oosterwijk, Jacqueline R.M. Plass, Danielle Meijer, Ivo Que, Marcel Karperien, Judith V.M.G. Bovée

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
22 Downloads (Pure)


Chondrosarcoma is a malignant cartilaginous tumor of the bone. Recently, mutations in isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) were identified in central chondrosarcomas. As chondrosarcomas are notoriously resistant to conventional treatment modalities, the need for model systems to screen new treatment options is high. We used two chondrosarcoma cell lines (CH2879 and SW1353) to generate a bioluminescent orthotopic chondrosarcoma mouse model. Cell lines were stably transduced with a lentiviral luciferase expression vector, and after clonal selection, luciferase-expressing clones were subcutaneously and orthotopically implanted in nude mice. Mice injected with CH2879 cells were treated with doxorubicin over a period of 6 weeks. Both cell lines resulted in tumor growth. CH2879 tumors were consistently larger than SW1353 tumors. No difference in size could be observed between subcutaneous and orthotopic tumors. Tumor growth could be monitored over time through assessment of luciferase activity, without harming the mice. Using this model, we show that doxorubicin does not have a significant effect on in vivo tumor growth. We describe an orthotopic chondrosarcoma mouse model that can be used to test new treatment strategies evolving from in vitro research
Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalVirchows Archiv
Issue number1
Publication statusPublished - 21 Oct 2015


  • 2023 OA procedure


Dive into the research topics of 'An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing'. Together they form a unique fingerprint.

Cite this